AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

4,023
Mkt Cap
$3.66B
Volume
2.00
52W High
$12.12
52W Low
$6.69
PE Ratio
819.72
AMRX Fundamentals
Price
$11.64
Prev Close
$11.52
Open
$11.53
50D MA
$10.37
Beta
1.18
Avg. Volume
1.52M
EPS (Annual)
-$0.3783
P/B
-33.42
Rev/Employee
$336,621.33
Loading...
Loading...
News
all
press releases
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 131,856 Shares of Stock
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 131,856 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold...
MarketBeat·12h ago
News Placeholder
More News
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $1,571,723.52 in Stock
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 131,856 shares of the company's stock in a transaction on Wednesday, November 12th. The shares were sold at an...
MarketBeat·2d ago
News Placeholder
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Zacks·3d ago
News Placeholder
FDA Approves Amneal's Generic Version Of GE's Omnipaque; Launch Expected In Q1 2026
(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), marking the first generic version of GE...
Nasdaq News: Markets·3d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High - Should You Buy?
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month High - Still a Buy...
MarketBeat·5d ago
News Placeholder
Los Angeles Capital Management LLC Has $1.61 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX
Los Angeles Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 238.0% during the 2nd quarter, according to its most recent 13F filing with...
MarketBeat·5d ago
News Placeholder
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Zacks·13d ago
News Placeholder
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·18d ago
News Placeholder
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +29.11% and +6.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago

Latest AMRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.